PrEP Descovy Oral denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for prep descovy oral are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Limits the Quantity of Descovy for PrEP — and How to Appeal

UnitedHealthcare applies quantity limits to many drugs as a cost-management tool, restricting how much of a medication can be dispensed per fill or per period. For Descovy (emtricitabine/tenofovir alafenamide) used as daily oral PrEP, a quantity-limit denial typically means the requested supply exceeded UHC's standard dispensing limit — for example, a 90-day supply requested on a plan that only authorizes 30-day fills, or a request that exceeds the per-period pill count. Quantity limits can also misfire when a refill is requested before the plan's internal clock has reset.

### Why This Is Appealable

Quantity limits must be clinically defensible, not merely cost-driven. For a once-daily oral medication like Descovy for PrEP, the FDA label defines the dosing regimen. If the requested quantity aligns with that regimen and the plan's limit effectively prevents consistent, uninterrupted use, the limit undermines the clinical purpose of PrEP — which requires adherence to provide protection. Gaps in PrEP coverage due to quantity restrictions carry real clinical consequences, which strengthens the medical-necessity argument for the requested supply.

The ACA preventive-services mandate may also be relevant: if quantity limits create a functional cost-sharing barrier to USPSTF-recommended PrEP for qualifying individuals, this may be independently impermissible under plans subject to the mandate.

### Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 or ACA §2719, you have the right to a full and fair review of the quantity-limit denial. File within the deadline on your denial notice.
• External review: After a final internal denial, you may request IRO review within approximately four months under ACA §2719.
• Expedited review: If delay would seriously jeopardize your health, request expedited review — typically decided within 72 hours.

### Documentation to Gather

1. FDA prescribing label for Descovy — confirms the once-daily dosing regimen and the clinical requirement for continuous, uninterrupted use to maintain protective levels. 2. Prescriber letter — should explain why the requested supply quantity is necessary for clinical adherence, why interruptions in PrEP are clinically significant, and how the requested quantity aligns with the FDA label. 3. UHC's quantity-limit policy — request the specific limit criteria used. Identify whether the limit is based on days' supply, units per period, or another metric, and show how the requested quantity conforms to or is necessitated by the FDA-approved regimen. 4. Pharmacy records — if this is a refill denial triggered by an early-refill edit, provide documentation of early use (e.g., travel, medication loss) or confirm the days' supply calculation is correct. 5. ACA preventive mandate citation — if applicable, note that quantity barriers on USPSTF-recommended PrEP may conflict with the mandate.

### Criteria-Mapping Structure

In your appeal, list each quantity-limit criterion from UHC's policy in a table and provide the specific FDA label text or clinical rationale that addresses it. If the limit is purely a dispensing-interval rule rather than a clinical threshold, make that argument explicitly: the FDA label, not the plan's dispensing calendar, defines the appropriate supply for this patient.

### Next Step

Before filing, call UHC and confirm the exact reason the quantity limit was triggered (early refill, excess units, supply cap, etc.). That information determines the most efficient appeal strategy. In many cases, a corrected days-supply calculation or a prescriber call to the pharmacy benefit manager resolves the issue without a formal appeal.